why choose us

First received: January 09, 2023

Clinical Trial: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Solid Tumor, Adult

Study Type: INTERVENTIONAL


Official Title: A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and

Brief Summary: The goal of this clinical trial is to learn about IOS-1002 in patients with solid tumors.The main questions it aims to answer are:* To determine the safety and tolerability of various doses of IOS-1002 administered alone and/or in combination with KEYTRUDA® (pembrolizumab) in a single dose escalation scheme* To determine the safety, tolerability and efficacy of a selected dose of IOS-1002 administered every 2 weeks alone and in combination with a PD-1 AntibodyThe study will be conducted in 3 parts:* Part A (Phase…

Read more